AKT1 and nasopharyngeal carcinoma: This study has shown that MK-2206 (AKT inhibitor) treatment had limited clinical effects for a cohort of patients with metastatic NPC who were not selected based on the gene expression of genomic aberration in P13K-AKT pathways.